News

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

David Fleischer, MD, discusses how the VITESSE trial positions the VIASKIN peanut patch as a promising option for children with peanut allergy.

Early identification of X-linked hypophosphatemia can prevent long-term skeletal deformities and improve outcomes through timely initiation of targeted therapy.

FDA okays once-weekly navepegritide for children with achondroplasia, boosting growth with strong trial data; rollout expected early Q2 2026.

The FDA has approved once-weekly somapacitan-beco for children aged 2.5 years and older with 3 separate growth indications.

A study found that hepatitis B virus birth dose vaccination rates fell from 83.5% in early 2023 to 73.2% by August 2025.

Druhan L. Howell, MD, discusses how new data on once-daily tapinarof show early, sustained improvements in itch and sleep outcomes.

A study found that cannabis use was associated with a doubled risk of psychotic and bipolar disorders.

The FDA has approved desmopressin acetate, the first formulation designed for individualized dosing in patients with central diabetes insipidus.

Jolanta Bernatoniene, MD, PhD, discusses data showing oral berotralstat significantly reduces moderate and severe attacks in children with hereditary angioedema.

The approval marks the first FDA-authorized treatment for allergic fungal rhinosinusitis, with trial data showing significant improvements in outcome measures.

From 2010 to 2022, urban hospitals expanded access to advanced neonatal services while rural communities experienced a net loss.

A study found cannabis use among adolescents aged 13 to 17 years was associated with a 2-fold increased risk of psychotic and bipolar disorders.

Although early introduction of allergenic foods remains a key strategy for preventing food allergies, rising infant emergency department visits may reflect mild, manageable reactions and uncertainty among families.

Suicide rates and attempts among Black youth have surged over the past decade, highlighting critical risk factors and the need for proactive screening and community-based prevention strategies.

New research highlights the fluctuating course of pediatric ADHD and the continued role of stimulant medications as first-line therapy.

A study highlights prior self-harm, traumatic brain injury, family instability, and social vulnerability as major risk factors associated with suicide among Black youth.

The gadopiclenol extension for use in infants and neonates offers high-quality MRI contrast enhancement at half the standard gadolinium dose.

National survey data show a 35% increase in child mental health conditions since 2016, with one-fourth of households reporting unmet treatment needs.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Children with Crohn disease had reduced microbial diversity and increased pro-inflammatory bacteria vs peers with disorders of brain-gut interaction.

Economic instability, food insecurity, discrimination, and low social support were associated with increased odds of pediatric long COVID.

Pediatricians decode the new dietary guidelines—more protein, zero added sugar under aged 11 years, full-fat dairy—plus what’s missing for kids’ health.

A study found that pediatric patients meeting burn center referral criteria were more likely to receive specialized care.

Findings demonstrate high completion rates and overall acceptability of the EQ-5D-Y-5L in routine outpatient pediatric specialty care.

New research shows widespread generative AI use among children and teens, prompting questions about potential impacts on social, mental, and sexual development.

Influenza antiviral treatment declined significantly among hospitalized children after COVID-19, highlighting gaps in guideline-recommended care.

Phase 3 KEPLER data showed vedolizumab achieved remission in nearly half of children with ulcerative colitis, with consistent safety and durable benefit.